Vanja Hoeben – Head of Benelux, Aspen
Vanja Hoeben oversees the Benelux cluster for South Africa-headquartered specialty and branded pharma firm Aspen. He describes the reorganisation that his organisation has undergone in the past few years, some…
Address: 98 Armstrong Avenue
La Lucia Ridge
Durban
4019,South Africa
Tel: +27 31 5808600
Web: http://www.aspenpharma.com/
South African-based JSE Limited listed Aspen is a supplier of branded and generic pharmaceuticals in approximately 100 countries across the globe and of consumer and nutritional products in selected territories.
Aspen is represented in South Africa, Australia, Hong Kong, Kenya, Tanzania, Uganda, Dubai, Germany, Ireland, Mauritius, Brazil, Mexico and Venezuela.
Aspen has 18 manufacturing facilities at 13 pharmaceutical manufacturing sites on five continents. Four of the sites are located in South Africa, four in Australia, and one in each of Kenya, Tanzania, Brazil, Mexico and Germany.
Aspen is the leading supplier of generic medicines to both the private and public sectors in South Africa.
Aspen has production capabilities for a wide variety of product types including tablets, capsules, steriles, injectables, oral contraceptives, nutritional products, lyophilised vials, cytotoxics, suppositories, vials, form-filled seals, liquids, semi-solids and specialist active pharmaceutical ingredients.
Vanja Hoeben oversees the Benelux cluster for South Africa-headquartered specialty and branded pharma firm Aspen. He describes the reorganisation that his organisation has undergone in the past few years, some…
Newly promoted to manage Aspen’s Middle East and Europe region, Daniel Vella Friggieri outlines the rationale behind the company’s strategic reconfiguration, how the South-Africa headquartered firm is looking to expand…
Aspen’s regional CEO for the Middle East, North Africa & Turkey, Daniel Vella Friggieri, provides insights into how the South African company’s federated model and decentralized management system translates into…
Aspen’s European Head Thomas Kerscher explains how the sale of the company’s thrombosis portfolio to Mylan has led to an organisational transformation in Europe with a leaner approach and an…
Miriam Rodriguez, general manager of Aspen Pharmacare Iberia, highlights the steps she has taken to set up the affiliate and how her past experiences have helped her. Furthermore, she breaks…
Franck Hamalian, general manager of the French affiliate of Aspen, a specialty and branded multinational pharmaceutical company from South Africa, discusses the Group’s unique business model which revolves around strategic…
Wojciech Sulimierski, general manager of Aspen Poland and CEE, discusses the opening of the regional operations in 2014 and the importance of the CEE region as the company establishes itself…
Alexandre França, CEO of Aspen Pharma Brazil, describes the transformation of the Brazilian organization over the past year, which allowed Aspen Brazil to establish itself as the best performing affiliate…
Carlos Alberto Florez, newly appointed general manager of Aspen Colombia, already has a very clear view on Aspen’s strategic direction, discussing the expansion of the infant nutrition segment and the…
Carlos Abelleyra Cordero, CEO Spanish Latin America of Aspen Labs, describes the rapid development of Aspen’s operational capacity throughout the region, in line with the company’s ambition to ultimately establish…
The head of Aspen sterile operations and managing director of Aspen NDB, reveals how their facility in France acts as the main platform for the group´s sterile business, a market…
From humble beginnings to one of the largest companies in Mauritius; the CEO of Aspen Global Incorporated Mauritius explains the significance of the Mauritian holding for one of the fastest…
Aspen Labs wants Latin America to be the third pillar of success for the company, and is doing it in a different way. The CEO for Spanish Latin America discusses…
Aspen Malaysia’s country manager details the company’s success in the country with a specific business model based on acquiring and remarketing originators. Although Aspen is a renowned generic player, market dynamics…
Marcelina Itchon, President & CEO of Aspen Philippines, talks about what drives Aspen’s success, why the Philippines was the first choice from which to build an Asian division, and the…
Marcelina Itchon, President & CEO of Aspen Philippines, talks about what drives Aspen’s success, why the Philippines was the first choice from which to build an Asian division, and the…
Marcelina Itchon, President & CEO of Aspen Philippines, talks about what drives Aspen’s success, why the Philippines was the first choice from which to build an Asian division, and the…
The line between research based pharmaceutical companies and generic companies is today less and less relevant, as we have seen in the past few years generic companies climb up the…
The Aspen Group identified Latin America as a “large developing market where it can leverage its substantial intellectual property portfolio and manufacturing infrastructure”. What was the original strategy behind getting…
The General Manager of Abbott’s Established Pharmaceuticals Division in South Africa, Gauta Phillip Mavundla illustrates how he is building the division’s presence within the region after the spinoff of AbbVie,…
Muhammad Bodhania, Managing Director of Medreich South Africa discusses potential strategic implications of the recent acquisition of Medreich by Meiji and the importance of local partnerships for global success. Can…
The CEO of BioTech Africa, Jason Lurie, evaluates the domestic and global landscape for diagnostic recombinant proteins, and highlights other developmental streams that have helped diversify the company’s portfolio. He…
The owner of Altis Biologics, Nick Duneas, illustrates the significance of the company’s flagship product, the Altis Osteogenic Bone Matrix (OBM) and how the company plans to commercialize the injectable bone…
The managing director of Trinity Pharma, Gaby Simaan (Jnr) depicts Trinity’s evolution from a regulatory consultancy into a fully commercialized pharmaceutical company, and how their unique position in the private…
The managing director of Galderma South Africa, Jenny Wright reveals the importance of the dermatology sector within the country’s healthcare system, as well as the role Galderma is playing in…
The Vice-Chairman of the Public Health Enhancement Fund talks about how the shortage of medical doctors and the fight against TB, HIV and AIDS in South Africa led the health…
The Head of the Department of Medicine at the Faculty of Health Science at the University of Cape Town reveals how their role is not only in training people to…
The managing director of Adcock Ingram’s prescription business, Ashley Pearce highlights the division’s strategic placement within the group’s overall activities, and how he plans on leveraging partnerships with various multinationals,…
The general manager of Ferring South Africa, Mercia Van Zyl discusses the company’s ambitious plans for the future under the slogan ‘People come first’, the placement of fertility under the…
The CEO of IPASA reveals how over the last ten months the priority has been to reach out to different stakeholders, rebuilding trust with the department of health, with patients…
The director of MRA Regulatory Consultants, Henriette Vienings reveals the important role they play in helping pharmaceutical companies navigate South Africa’s regulatory environment, as well as the importance of the…
See our Cookie Privacy Policy Here
